Top

Published in:

01-04-2010 | Review Article

Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy

Authors: Waqar Haque, Huseyin Kadikoy, Omar Pacha, Joseph Maliakkal, Vu Hoang, Abdul Abdellatif

Published in: Rheumatology International | Issue 6/2010

Abstract

Osteonecrosis is commonly present in patients with antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE). Treatment of this condition remains extremely controversial. We present a treatment strategy of avascular necrosis of the knee in a patient with catastrophic antiphospholipid syndrome with a history of SLE and APS. Aggressive treatment with 12 rounds of plasmapheresis, intravenous immunoglobulin, rituximab, and cylophosphamide led to the patient’s recovery with no recurrence of symptoms during 16 months of follow up. In this report, we further discuss the pathogenesis of osteonecrosis and current understanding of the treatment of this disease.

Abeles M, Urman JD, Rothfield N (1978) Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med 138:750–754CrossRefPubMed

Dimant J, Ginzler EM, Diamond HS et al (1978) Computer analysis of factors influencing the appearance of aseptic necrosis in patients with SLE. J Rheumatol 5:136–141PubMed

Miyakis S, Lockshin MD, Atsumi T et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed

Gorshtein A, Levy Y (2007) Orthopedic involvement in antiphospholipid syndrome. Clin Rev Allergy Immunol 32:167–171CrossRefPubMed

Agarwala S et al (2005) Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. Rheumatology 44:352–359CrossRefPubMed

Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 58:15–25CrossRefPubMed

Miyakis S, Lockshin MD, Atsumi I et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4:295–306CrossRefPubMed

Bick RL, Baker WF (1992) Anticardiolipin antibodies and thrombosis. Hematol Oncol Clin North Am 6:1287–1299PubMed

Triplett DA (1993) Antiphospholipid antibodies and thrombosis: a consequence, coincidence, or cause? Arch Pathol Lab Med 117:78–88PubMed

10.

Bick RL, Baker WF (1994) The antiphospholipid and thrombosis syndromes. Med Clin North Am 78:667–684PubMed

11.

Asherson RA, Khamashta MA, Ordi-Ros J et al (1989) The “primary” antiphospholipid syndrome: major clinical and serological features. Medicine 68:366–374CrossRefPubMed

12.

Nagasawa K, Ishii Y, Mayumi T et al (1989) Avascular necrosis of bone in systemic lupus erythematosus: possible role of haemostatic abnormalities. Ann Rheum Dis 48:672–676CrossRefPubMed

13.

Alijotas J, Argemi M, Barquinero J (1990) Kienbock’s disease and antiphospholipid antibodies. Clin Exp Rheumatol 8:297–298PubMed

14.

Seleznick MJ, Silveira LH, Espinoza LR (1991) Avascular necrosis associated with anticardiolipin antibodies. J Rheumatol 18:1416–1417PubMed

15.

Vela P, Batlle E, Salas E, Marco P (1991) Primary antiphospholipid syndrome and osteonecrosis (letter). Clin Exp Rheumatol 9:545–546PubMed

16.

Asherson RA, Liote F, Page B et al (1993) Avascular necrosis of bone and antiphospholipid antibodies in systemic lupus erythematosus. J Rheumatol 20:284–288PubMed

17.

Migliaresi S, Picillo U, Ambrosone L, Di Plama G et al (1994) Avascular necrosis in patients with SLE: relation to corticosteroid therapy and anticardiolipin antibodies. Lupus 3:37–41CrossRefPubMed

18.

Oosting JD, Derksen RHWM, Bobbink IWG et al (1993) Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C or protein S: an explanation for their pathogenic mechanism? Blood 83:2618–2625

19.

Marciniak E, Romond EH (1989) Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood 74:2426–2432PubMed

20.

Malia RG, Kitchen S, Greaves M, Preston FE (1990) Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 76:101–107CrossRefPubMed

21.

Ieko M, Ichikawa K, Triplett DA (1999) β2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies. Arthritis Rheum 42:167–174CrossRefPubMed

22.

Escolar G, Font J, Reverter JC (1992) Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Arterioscler Thromb 12:196–200PubMed

23.

Campbell AL, Pierangeli SS, Wellhausen S, Harris EN (1995) Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost 73:529–534PubMed

24.

Khamashta MA, Harris EN, Gharavi AE (1988) Immune mediated mechanism for thrombosis:antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 47:849–854CrossRefPubMed

25.

Kornberg A, Blank M, Kaufman S, Shoenfeld Y (1994) Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 153:1328–1332PubMed

26.

Simantov R, LaSala JM, Lo SK (1995) Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest 96:2211–2219CrossRefPubMed

27.

Del Papa N, Guidali L, Sala A (1997) Endothelial cells as target for antiphospholipid antibodies—human polyclonal and monoclonal anti-β2 glycoprotein I antibodies react in vitro with endothelial cells through adherent β2 glycoprotein I and induce endothelial activation. Arthritis Rheum 40:551–561CrossRefPubMed

28.

Cuadrado MJ, López-Pedrera C, Khamashta MA (1997) Thrombosis in primary antiphospholipid syndrome—a pivotal role for monocyte tissue factor expression. Arthritis Rheum 40:834–841CrossRefPubMed

29.

Amengual O, Atsumi T, Khamashta MA, Hughes GRV (1998) The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost 79:276–281PubMed

30.

Vega-Ostertag M, Casper K, Swerlick R et al (2005) Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum 52:1545–1554CrossRefPubMed

31.

Jones LC, Mont MA, Le TB et al (2003) Procoagulants and osteonecrosis. J Rheumatol 30:783–791PubMed

32.

Mont MA, Ulrich SD, Seyler TM (2007) Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis. J Rheumatol 34:466–468PubMed

33.

Glueck CJ, Freiberg R, Glueck HI et al (1994) Hypofibrinolysis: a common, major cause of osteonecrosis. Am J Hematol 45:156–166CrossRefPubMed

34.

Glueck CJ, Rorick MH, Schmerler M et al (1995) Hypofibrinolytic and atherogenic risk factors for stroke. J Lab Clin Med 125:319–325PubMed

35.

Glueck CJ, Glueck HI, Greenfield D et al (1994) Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediatr Res 35:383–388PubMed

36.

Gruppo R, Glueck CJ, McMahon RE, Bouquot J, Rabinovich BA, Becker A, Tracy T, Wang P (1996) The pathophysiology of alveolar osteonecrosis of the jaw: anticardiolipin antibodies, thrombophilia, and hypofibrinolysis. J Lab Clin Med 127:481–488CrossRefPubMed

37.

Mont MA, Glueck CJ, Pacheco IH, Wang P, Hungerford DS, Petri M (1997) Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24:654–662PubMed

38.

Darabi K, Berg AH (2006) Rituximab can be combined with daily plasma exchange to achieve effective B-cell depletion and clinical improvement in acute autoimmune TTP. Am J Clin Path 125:592–597PubMed

39.

Allford S, Machin S (2003) Guidelines on the diagnosis and management of the thrombotic microangiopathic haemolytic anaemias. Br J Haematol 120:556–573CrossRefPubMed

40.

Otsubo S, Nitta K, Yumura W, Nihei H, Mori N (2002) Antiphospholipid syndrome treated with prednisolone, cyclophosphamide and double-filtration plasmapheresis. Intern Med 41:725–729CrossRefPubMed

41.

Aaron RK (1998) Osteonecrosis: etiology, pathophysiology, and diagnosis. The adult hip, Lippincott-Raven Publishers, Philadelphia, pp 451–466

Title: Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy
Authors: Waqar Haque
Huseyin Kadikoy
Omar Pacha
Joseph Maliakkal
Vu Hoang
Abdul Abdellatif
Publication date: 01-04-2010
Publisher: Springer-Verlag
Published in: Rheumatology International / Issue 6/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI: https://doi.org/10.1007/s00296-009-1269-9

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2010

Study of autoantibodies in patients with keratoconjunctivitis sicca infected by the human T cell lymphotropic virus type 1

Severity of Carpal tunnel syndrome assessed with high frequency ultrasonography

Rapidly progressive neuropathic arthropathy of the knee in possible association with a huge extruded cervical intervertebral disc herniation

Adiponectin and leptin serum concentrations in patients with rheumatoid arthritis

A clinical picture of chronic polyarticular tophaceous gout

Abatacept as an option therapy in difficult to treat psoriatic arthritis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page